Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
RLJ Lodging Trust
RLJ
$1.67B
| $2.15M | ﹤0.01% |
288,028
+23,781
| +9% | +$173K |
|
2852
Marcus & Millichap
MMI
$1.2B
| $2.14M | ﹤0.01% |
78,350
+6,911
| +10% | +$200K |
|
2853
Quanex
NX
$981M
| $2.13M | ﹤0.01% |
138,794
+20,683
| +18% | +$292K |
|
2854
Upbound Group
UPBD
$1.15B
| $2.13M | ﹤0.01% |
121,546
+16,178
| +15% | +$313K |
|
2855
Monte Rosa Therapeutics
GLUE
$1.35B
| $2.13M | ﹤0.01% |
135,984
+63,029
| +86% | +$849K |
|
|
VLRS
2856
Controladora Vuela Compania de Aviacion
VLRS
$922M
| $2.13M | ﹤0.01% |
+239,805
| New | +$1.74M |
|
2857
UWM Holdings
UWMC
$2.61B
| $2.13M | ﹤0.01% |
485,832
+382,735
| +371% | +$2.06M |
|
2858
Tecnoglass Holdings Inc.
TGLS
$1.87B
| $2.13M | ﹤0.01% |
42,288
+6,940
| +20% | +$379K |
|
2859
ARK Innovation ETF
ARKK
$6.54B
| $2.13M | ﹤0.01% |
27,659
-180,369
| -87% | -$14.9M |
|
2860
Enviri
NVRI
$564M
| $2.13M | ﹤0.01% |
118,583
+11,455
| +11% | +$171K |
|
2861
American Superconductor
AMSC
$1.53B
| $2.12M | ﹤0.01% |
73,805
+11,242
| +18% | +$486K |
|
2862
Tennant Co
TNC
$1.15B
| $2.12M | ﹤0.01% |
28,810
+2,182
| +8% | +$167K |
|
|
MOFG
2863
DELISTED
MidWestOne Financial Group
MOFG
| $2.12M | ﹤0.01% |
55,102
+6,455
| +13% | +$235K |
|
2864
CALL
Amplify Energy
AMPY
$200M
| $2.12M | ﹤0.01% |
+464,000
| New | +$2.31M |
|
2865
ProShares UltraPro QQQ
TQQQ
$38.7B
| $2.12M | ﹤0.01% |
40,200
+38,200
| +1,910% | +$2.05M |
|
|
CFLT
2866
CALL
DELISTED
Confluent
CFLT
| $2.12M | ﹤0.01% |
70,000
+45,000
| +180% | +$1.1M |
|
2867
PUT
Wave Life Sciences
WVE
$1.02B
| $2.11M | ﹤0.01% |
+124,100
| New | +$1.26M |
|
|
ARI
2868
Apollo Commercial Real Estate
ARI
$886M
| $2.11M | ﹤0.01% |
217,800
-319,492
| -59% | -$3.2M |
|
2869
Melco Resorts & Entertainment
MLCO
$2.14B
| $2.11M | ﹤0.01% |
278,502
+202,600
| +267% | +$1.7M |
|
2870
Zymeworks
ZYME
$1.83B
| $2.11M | ﹤0.01% |
79,966
-119,057
| -60% | -$2.6M |
|
|
DMC
2871
Del Monte Corp
DMC
$1.44B
| $2.11M | ﹤0.01% |
59,087
+3,848
| +7% | +$137K |
|
2872
Innovative Industrial Properties
IIPR
$1.67B
| $2.1M | ﹤0.01% |
44,435
+4,078
| +10% | +$211K |
|
2873
PUT
J.M. Smucker
SJM
$12.9B
| $2.1M | ﹤0.01% |
21,500
-231,600
| -92% | -$23.9M |
|
2874
Arhaus
ARHS
$1.37B
| $2.1M | ﹤0.01% |
187,180
+762
| +0.4% | +$7.91K |
|
2875
Sonic Automotive
SAH
$2.51B
| $2.1M | ﹤0.01% |
33,913
+12,156
| +56% | +$805K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.